The present study attempted to define the role of hepatic Niemann-Pick C1-like 1 (NPC1L1), a cholesterol transporter, in hepatic insulin resistance as well as hepatic steatosis. The inhibition of NPC1L1 and its molecular consequences were examined in Zucker obese fatty (ZOF) rats and cultured steatotic hepatocytes using ezetimibe, a pharmacoloigcal inhibitor of NPC1L1, and short hairpin RNA (shRNA) of NPC1L1. Ezetimibe improved hepatic insulin signaling as well as hepatic steatosis in ZOF rats. It also restored insulin sensitivity in steatotic hepatocytes in vitro through a reduction in hepatic reactive oxygen species (ROS) generation, JNK activation, and ER stress. In addition, ezetimibe recovered insulin-induced Akt activation and reduced gluconeogenic genes in the liver of ZOF rats and cultured steatotic hepatocytes. Transfection of NPC1L1 shRNA into hepatocytes also reduced ROS generation and ER stress. These results indicate that NPC1L1 contributes to hepatic insulin resistance through cholesterol accumulation, and its inhibition could be a potential therapeutic target of hepatic insulin resistance. cholesterol transporter; oxidative stress; endoplasmic reticulum stress THE SYSTEMIC LEVEL OF CHOLESTEROL is tightly regulated by de novo biosynthesis in the liver, dietary absorption in the intestines, and biliary excretion (15). Intestinal Niemann-Pick C1-like 1 (NPC1L1) plays a pivotal role in cholesterol absorption (1), and ezetimibe (Ez), a pharmacological inhibitor of cholesterol absorption (5), has been shown to target NPC1L1 (11). Unlike mouse NPC1L1 protein, expressed predominantly in the intestines, human and rat NPC1L1 are also abundantly expressed in the liver (1). The exact functions of hepatic NPC1L1 remain unknown. A recent study conducted in our laboratory (6) demonstrated favorable effects of Ez on hepatic steatosis in the livers of Zucker obese fatty (ZOF) rats, a genetic model of obesity and insulin resistance (22, 30). Furthermore, Ez lowered fasting insulin levels and improved high-fat-induced glucose tolerance (6). However, the direct involvement of hepatic NPC1L1 during this process is not fully understood.
THE SYSTEMIC LEVEL OF CHOLESTEROL is tightly regulated by de novo biosynthesis in the liver, dietary absorption in the intestines, and biliary excretion (15) . Intestinal Niemann-Pick C1-like 1 (NPC1L1) plays a pivotal role in cholesterol absorption (1) , and ezetimibe (Ez), a pharmacological inhibitor of cholesterol absorption (5) , has been shown to target NPC1L1 (11) . Unlike mouse NPC1L1 protein, expressed predominantly in the intestines, human and rat NPC1L1 are also abundantly expressed in the liver (1) . The exact functions of hepatic NPC1L1 remain unknown. A recent study conducted in our laboratory (6) demonstrated favorable effects of Ez on hepatic steatosis in the livers of Zucker obese fatty (ZOF) rats, a genetic model of obesity and insulin resistance (22, 30) . Furthermore, Ez lowered fasting insulin levels and improved high-fat-induced glucose tolerance (6) . However, the direct involvement of hepatic NPC1L1 during this process is not fully understood.
Cholesterol accumulation in hepatocytes accelerates tumor necrosis factor-␣ (TNF␣) or lipopolysaccaride (LPS)-mediated steatosis (14, 22, 24) through oxidative stress generated in mitochondria. Moreover, accumulation of free cholesterol (FC) in endoplasmic reticulum (ER) activates unfolded protein response (UPR) in macrophages (7, 19, 23, 29) . UPR-mediated ER stress is also associated with insulin resistance (17, 27) . These findings point to a causative connection between cholesterol accumulation and inflammation in the development of insulin resistance.
In the present study, we tried to elucidate the role of NPC1L1 on hepatic lipid accumulation and subsequent insulin resistance using Ez and short hairpin (sh)RNA. Our findings support a novel role for hepatic cholesterol accumulation and its modulation in hepatic steatosis and insulin resistance.
MATERIALS AND METHODS
Cell culture and reagents. Ez was supplied by Schering-Plough. Ez was resolved in dimethyl sulfoxide (DMSO), and DMSO was used as control. Human primary hepatocytes (DS Pharma Biomedical) were cultured in CS-2.5 Complete Serum-Free Medium (Cell Systems) and Caco2 and HuH7 cells in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. HuH7 cells were also cultured in DMEM without serum in stimulation. Other reagents used in this study were water-soluble cholesterol (Sigma) and methyl-␤-cyclodextrin (Sigma). Cell viability was determined using Multiplexed Viability and Cytotoxicity Assays (Promega). Mitochondria from the cells and livers were isolated using a Mitochondria Isolation Kit (Pierce), following the manufacturer's protocol. Total glutathione was determined with a Total Glutathione Quantification Kit (Dojindo). AntiAkt (Cell Signaling Technology), anti-phospho-Akt1/2/3 (Ser 473 ; Santa Cruz Biotechnology), anti-SAPK/JNK, anti-phospho-SAPK/ JNK (Thr 183 /Tyr 185 ; Cell Signaling Technology), anti-p38 MAP kinase, anti-phospho-p38 MAP kinase (Thr 180 /Tyr 182 ; Cell Signaling Technology), anti-actin (Sigma), and anti-NPC1L1 (Novus Biologicals) were used in this study.
Animals. Male ZOF rats (7 wk of age; Japan SLC) were housed with a regular 12:12-h light-dark cycle. Rats were fed a low-fat diet (3.4 kcal/g) with 10% kcal fat, 20% kcal protein, and 70% kcal carbohydrate for 1 wk, followed by 4 wk of a high-fat diet (5.2 kcal/g) with 60% kcal fat (soybean oil/lard ϭ 1:10), 20% kcal protein (casein/L-cysteine ϭ 60:1), and 20 kcal% carbohydrate (maltodextrin 10/sucrose ϭ 2:1) with (Ez) or without (Ve) 0.008% wt/wt Ez. Rats had free access to water and the foods until the experiments. Blood samples were collected from the tail vein to measure blood glucose, insulin, and lipid concentrations (see Supplemental Fig. S1 ; Supplemental Material is available at the AJP-Endocrinology and Metabolism web site). Rats were euthanized under anesthesia induced by intraperitoneal injection of pentobarbital sodium (50 mg/kg). Livers were perfused by phosphate-buffered saline (PBS) and isolated and rapidly frozen in liquid nitrogen. They were preserved at Ϫ80°C until the examination. The study was reviewed and approved by the Animal Care and Use Committee of Tokyo Medical and Dental University.
Intraperitoneal insulin tolerance test and pyruvate tolerance test. At 4 wk after treatment of ZOF rats with the vehicle (Ve) or Ez, fasting (16 h) rats were injected intraperitoneally with 0.75 IU/kg body wt of insulin or 1.5 g/kg body wt of pyruvate. Blood glucose levels were subsequently measured by blood glucose test meter (Sanwa).
Measurements of total cholesterol and triglyceride. Cells and mitochondrial pellets were washed and separately homogenized and extracted with a chloroform-methanol (2:1 vol/vol) solution, after which the organic phase was dried and resolubilized in 2-propanol containing 10% Triton X-100. Total cholesterol and triglyceride levels were determined using enzymatic kits, as described previously (6) .
Visualization of intracellular superoxide. Oxidation-dependent fluorescent dye dihydroethidium (DHE; Sigma) was used to evaluate the production of superoxide. Unfixed frozen livers were cut into 5-mthick sections, which were placed on glass slides. Twenty micromolars of DHE was applied to the surface of each tissue section and in the dishes of cultured cells, and the slides and dishes were incubated in a light-protected humid chamber at 37°C for 30 min. Images were obtained with a microscope (IX70; Olympus) equipped with a krypton-argon laser. Laser and power settings were identical during acquisition of images of various specimens. Fluorescence was detected with a 585-nm long-pass filter.
Measurements of mRNA. Total RNA was isolated from frozen tissue samples, and cells were washed by PBS using an RNeasy mini kit (Qiagen) and then converted to cDNA using a reverse-transcript method with Superscript III RNase H Reverse Transcriptase (Invitrogen). Real-time PCR was performed with an ABI PRISM 7900HT sequence detection system (Applied Biosystems) using SYBR Green dye (Roche Diagnosis). Relative mRNA transcript levels were calculated using the comparative cycle threshold method, which is based on the difference in cycle threshold values between the target mRNA and ␤-actin, which is used as an internal control. The primer sets utilized are described in Table 1 .
RNA interference. For gene silencing of NPC1L1 expression in HuH7 cells, DNA-based vector-mediated RNAi technology was used. Synthetic oligonucleotides containing the human NPC1L1 target sequences (5Ј-ccggtccagctacaggtat-3Ј) were cloned into pBAsi hU6 DNA (Takara). Control scramble and NPC1L1 target vectors were then separately transfected using Lipofectamine VTX (Invitrogen), following the manufacturer's protocol.
Western blot analysis. Western blot analysis was performed using lysates prepared from primary human hepatocytes, HuH7 cells, and frozen liver samples, as described previously (6) . An equal amount of protein (10 g) from each condition was subjected to 5-20% SDS-PAGE. Immunoreactive proteins were detected using an enhanced chemiluminescence kit (Amersham Biosciences).
Statistical analysis. 
AAGAGCGTGCCCTACTTCAA CTGTTGTTGTCCATGGATGC PEPCK, phosphoenolpyruvate carboxykinase; G-6-Pase, glucose-6-phosphatase; ABCG5 and -8, ATP-binding cassette, subfamily G, members 5 and 8; FXR, farnesoid X receptor-␣; SHP, short heterodimer partner; SREBP-1c and -2, sterol regulatory element-binding protein-1c and -2; ChREBP, carbohydrate response element-binding protein; NCF1 and -2, neutrophil cytosolic factor 1 and 2; COX2, cyclooxigenase-2; PERK, protein kinase-like endoplasmic reticulum kinase; XBP1s, spliced form of X-box-binding protein-1; ATF6, activating transcription factor 6; CHOP, C/EBP homologous protein Niemann-Pick C1-like 1; FoxO1, forkhead transcription factor.
RESULTS
Effects of NPC1L1 blockade on glucose metabolism and insulin sensitivity in ZOF rats. In our previous observations (6), NPC1L1 blockade by Ez improved glucose homeostasis, judged by a glucose tolerance test. To assess the impact of NPC1L1 blockade on systemic insulin sensitivity in ZOF rats, an insulin tolerance test was conducted by intraperitoneally administering insulin. As shown in Fig. 1A , whereas insulin failed to decrease blood glucose level in the Ve group, it significantly decreased blood glucose in the Ez group, indicating that NPC1L1 blockade improves glucose homeostasis and systemic insulin sensitivity.
To monitor the effect of Ez on hepatic glucose production, we performed a pyruvate tolerance test by intraperitoneal administration of pyruvate, a precursor in the synthesis of glucose in the liver. As shown in Fig. 1B , pyruvate administration induces a massive elevation of blood glucose in the Ve group, whereas elevation of blood glucose was significantly lower in Ez group, suggesting a reduction of hepatic gluconeogenesis after Ez treatment.
Furthermore, to examine the effect of NPC1L1 blockade on hepatic insulin sensitivity, exogenous insulin-induced phosphorylation of Akt, a key molecule of insulin signaling, was quantified by Western blotting. As shown in Fig. 1C , Ez increased the phosphorylation of Akt, which indicates that NPC1L1 blockade increases hepatic insulin sensitivity.
We then analyzed the expression profiles of representative molecules involved in hepatic metabolic pathways (Fig. 1D) . Ez significantly reduced the rate-limiting enzymes associated with gluconeogenesis, such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase). It also reduced cholesterol transport proteins [ATP-binding cassette, subfamily G, members 5 (ABCG5) and 8 (ABCG8)] that regulate biliary cholesterol secretion. In addition, we also observed a moderate induction of farnesoid X receptor-␣ (FXR), a ligand-activated nuclear receptor transcription factor, and its target gene short heterodimer partner (SHP) following Ez treatment. In contrast, sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate response elementbinding protein (ChREBP), transcription factors involved in Fig. 1 . Effects of Niemann-Pick C1-like 1 (NPC1L1) blockade on glucose metabolism and insulin sensitivity in Zucker obese fatty (ZOF) rats. A: blood glucose changes following intraperitoneal injection of insulin at 4 wk after treatment of ZOF rats with the vehicle (Ve) or ezetimibe (Ez) (n ϭ 3 for each treatment). B: blood glucose changes following intraperitoneal injection of pyruvate at 4 wk after treatment of ZOF rats with the Ve or Ez (n ϭ 3 for each treatment). C: at 4 wk following treatment of ZOF rats with the Ve or Ez, the livers were collected at 5 min after injection of 0.75 IU/kg insulin or control PBS through the portal vein, and then insulin-induced Akt phosphorylation (p-Akt) was detected in whole cell extracts (n ϭ 4 for each treatment). D: at 4 wk following treatment of ZOF rats with the Ve or Ez, total RNA was isolated from the livers, and then mRNA expression levels of key metabolic regulators were determined using real-time PCR (n ϭ 4 for each treatment). *P Ͻ 0.05. AU, arbitrary units; ITT, insulin tolerance test; PTT, pyruvate tolerance test; PEPCK, phosphoenolpyruvate carboxykinase; G-6-Pase, glucose-6-phosphatase; ABCG5 and -8, ATP-binding cassette, subfamily G, members 5 and 8; FXR, farnesoid X receptor; SHP, short heterodimer partner; SREBP-1c and -2, sterol regulatory element-binding protein-1c and -2; ChREBP, carbohydrate response element-binding protein.
the expression of lipogenic genes in response to insulin and glucose, were significantly decreased by Ez.
Effects of Ez on glucose metabolism and insulin sensitivity in cultured hepatocytes. Next, we examined the direct effects of Ez on insulin signaling in cultured human primary hepatocytes stimulated with FC and LPS/TNF in vitro. First, we examined the mRNA expression level of NPC1L1 in cultured human intestinal cell line (Caco2 cells), primary hepatocytes, and cultured human liver cell line (HuH7 cells) (Fig. 2A) . After abundant expression of NPC1L1 in these hepatocytes was confirmed, the effect of Ez on cholesterol uptake was examined. Free cholesterol increased total cholesterol as well as triglyceride in primary hepatocytes, both of which were reduced by Ez (Fig. 2B) . We then assessed the insulin-induced phosphorylation of Akt in these hepatocytes. Although inflammatory cytokines such as TNF or LPS alone did not affect Akt phosphorylation in cultured hepatocytes, costimulation of FC and TNF (FC/TNF) or FC and LPS (FC/LPS) significantly reduced the Akt phosphorylation that was restored by Ez (Fig.  2C ). As shown in Fig. 2D , stimulation with FC/LPS induced gluconeogenic genes such as PEPCK and G-6-Pase in hepatocytes, and the induction of PEPCK, but not G-6-Pase, was recovered by Ez. Ez also restored the FC/LPS-mediated reduction of FXR. Similar expression profiles were observed with SHP in hepatocytes. Furthermore, Ez significantly attenuated FC/LPS-induced expressions of SREBP-1c and ChREBP.
Effects of Ez on mitochondrial-and ER stress-induced ROS in hepatocytes.
Recent studies have indicated that reactive oxygen species (ROS) play a role in insulin resistance (8, 18, 19, 21, 32) . Thus DHE-associated fluorescence, an indicator of ROS, in primary hepatocytes was examined. As shown in Fig. 3A , FC/TNF increased DHE-associated fluorescence in hepatocytes, which was decreased by Ez. The expression levels of neutrophil cytosolic factor (NCF)1 and 2, subunits of NADPH oxidase, were upregulated by FC/TNF which was downregulated by Ez. Previous reports suggested that steatotic ROS production is stimulated by increased mitochondrial cholesterol and decreased mitochondrial glutathione (mGSH) levels (22, 24) . As expected, Ez significantly attenuated mitochondrial cholesterol and restored mGSH levels (Fig. 3, B and C) . Other studies have shown that ROS-dependent activation of JNK plays a role in the development of insulin resistance (3, Fig. 2 . Effects of Ez on glucose metabolism and insulin sensitivity in steatotic hepatocytes. A: total RNA was isolated from the 3 types of cells, and mRNA expression levels of NPC1L1 were determined using real-time PCR (n ϭ 3 for each treatment). *P Ͻ 0.01. B-D: primary human hepatocytes were depleted of cholesterol by incubation in 1.5% methyl-␤-cyclodextrin (CDX) for 60 min. The cells were washed and incubated with or without Ez (25 M), and then free cholesterol (FC; 50 g/ml) was added to the medium after 60 min. B: after 24 h, total cholesterol (T-Chol) and triglyceride (TG) were extracted from the cells and quantified (n ϭ 4 for each treatment). *P Ͻ 0.05; **P Ͻ 0.01. C and D: after 60 min, TNF (25 ng/ml) or LPS (100 ng/ml) was added to the medium. C: after 24 h, the cells were stimulated for 15 min with insulin (Ins; 100 nM), and then Akt phosphorylation was detected in whole cell extracts (n ϭ 3 for each treatment). *P Ͻ 0.05. D: after 24 h, total RNA was isolated from the cells, and mRNA expression levels of key metabolic regulators were determined using real-time PCR (n ϭ 3 for each treatment). *P Ͻ 0.05; **P Ͻ 0.01. 16, 28) . In the present study, Ez modulated FC/TNF-induced activation of JNK (Fig. 3D) . Cholesterol accumulation also caused ER stress, which plays a role in hepatic insulin resistance (17, 25) . Thus ER stress-related molecules in hepatocytes were quantified after treatment. Ez significantly decreased FC-mediated activation of p38, a regulator of CHOP induction (7) (Fig. 3E) . In addition, FC significantly upregulated RNAactivated protein kinase-like ER kinase (PERK), activating transcription factor 6 (ATF6), forkhead transciption factor (FoxO1), and the spliced form of X-box-binding protein-1 (XBP1s) and C/EBP homologous protein (CHOP) to a lesser extent (Fig. 3F) .
Effect of NPC1L1 blockade on ROS production in the livers of ZOF rats. The contribution of ROS production in the liver was determined in ZOF rats in vivo. First, Ez reduced mitochondrial cholesterol accumulation in the liver (Fig. 4A) . Prominent DHE-associated fluorescence was observed in the livers of the control rats, whereas that intensity was significantly reduced after Ez treatment (Fig. 4B) . Ez also increased mGSH levels (Fig. 4C) and decreased the phosphorylation of JNK and p38 in the livers of ZOF rats (Fig. 4D) . In addition, high-fat-induced expression of NADPH oxidases NCF1 and NCF2 and inflammatory molecules TNF, interleukin-6 (IL-6), IL-1␤, and cyclooxigenase-2 (COX2) were significantly inhibited by Ez treatment (Fig. 4E) . Furthermore, the expressions of ER stress markers (PERK, ATF6, and CHOP) were significantly decreased in Ez-treated rats (Fig. 4E) .
Effect of knockdown of NPC1L1 in hepatocytes. The role of NPC1L1 in hepatic HuH7 cells was then critically assessed by gene silencing of the NPC1L1 gene using shRNA. Preliminary experiments confirmed that shRNA against NPC1L1 decreased NPC1L1 protein expression (Fig. 5A ). In addition, shRNA against NPC1L1 significantly reduced total cholesterol contents in both cytosol and mitochondria of HuH7 cells (Fig. 5B) . Introduction of shRNA against NPC1L1 restored TNF/FCattenuated insulin-induced Akt phosphorylation (Fig. 5C ). In addition, shRNA against NPC1L1 decreased steatosis-induced ER stress in hepatic HuH7 cells (Fig. 5D) . Furthermore, shRNA against NPC1L1 decreased ROS production (Fig. 5E) , NCF1, and NCF2 (Fig. 5F ) and activated JNK (Fig. 5G) and  p38 (Fig. 5H) .
DISCUSSION
In the current study, we found that hepatic NPC1L1 plays a pivotal role in insulin resistance as well as steatosis in the liver. Fig. 3 . Effects of Ez on mitochondrial-and endoplasmic reticulum stress-induced reactive oxygen species (ROS) in hepatocytes. Primary human hepatocytes were depleted of cholesterol by incubation in 1.5% CDX for 60 min and then washed and incubated with or without Ez (25 M). After 60 min, FC (50 g/ml) was added to the medium. A-D: after 60 min, TNF (25 ng/ml) was added to the medium. A: after 24 h, the amount of ROS was visualized by dihydroethidium (DHE) staining and quantified (n ϭ 3 for each treatment). Total RNA was isolated from the cells, and the mRNA expression levels were determined using real-time PCR (n ϭ 3 for each treatment). B: after 24 h, mitochondria were isolated from the cells, and cholesterol was extracted and quantified (n ϭ 3 for each treatment). C: after 24 h, cytosol and mitochondria were isolated from the cells, and total glutathione was quantified (n ϭ 3 for each treatment). D: after 24 h, the cells were stimulated for 15 min with or without TNF (25 ng/ml), and then JNK phosphorylation was detected in whole cell extracts (n ϭ 3 for each treatment). E: after 6 h, whole cell extracts were collected, and p38 phosphorylation was detected (n ϭ 3 for each treatment). F: after 6 h, total RNA was isolated from the cells, and mRNA expression levels were determined using realtime PCR (n ϭ 3 for each treatment). *P Ͻ 0.05; **P Ͻ 0.01. FoxO1, forkhead transcription factor.
The three major findings of the present study were demonstrated. First, ezetimibe, a specific inhibitor of NPC1L1, restores hepatic insulin sensitivity in ZOF rats in vivo (Fig. 1) as well as steatotic hepatocytes in vitro (Fig. 2) . Second, ezetimibe decreases ROS production, JNK activation, and ER stress in steatotic hepatocytes (Fig. 3) as well as in the livers of ZOF rats (Fig. 4) . And finally, gene silencing of NPC1L1 by shRNA decreases cholesterol accumulation and ROS production and improves insulin resistance in HuH7 cells (Fig. 5) .
Hepatic steatosis is one of the major phenotypes of metabolic disorders, and underlying mechanisms of the condition involve both lipid accumulation and inflammatory reactions. Therefore, cholesterol incorporation in the liver may have an effect on the pathogenesis of hepatic steatosis. Previously, we and another group showed that ezetimibe improves not only systemic hyperlipidemia but also hepatic steatosis and fibrosis by lowering hepatic TG and total cholesterol levels in rats and mice, respectively (6, 34) . In the present study, we thus studied the potential contribution of hepatic cholesterol incorporation for hepatic steatosis and subsequent insulin resistance.
In (Fig. 2B) , FC increases both total cholesterol and TG in hepatocytes, which indicates that FC causes lipid accumulation. In addition, previous findings suggested a role of FC in TNF-and LPS-induced steatosis in the liver (24) . To mimic steatotic conditions in vitro, we stimulated cultured hepatocytes with both FC and inflammatory cytokines and examined whether cholesterol uptake via NPC1L1 in the liver might have a role in that process. In fact, the expression levels of insulin-associated genes in hepatocytes (Fig.  2D) showed a similar pattern to those found in liver of ZOF rats (Fig. 1D) . In addition, blockade of NPC1L1 in cultured hepatocytes by ezetimibe significantly reduced cholesterol uptake and subsequently recovered key molecules involved in insulin signaling, such as Akt phosphorylation and gluconeogenic enzymes (PEPCK and G-6-Pase). Interestingly, ezetimibe activated the FXR-SHP pathway (Figs. 1D and  2D) , which regulates the enterohepatic recycling and biosynthesis of bile acids (30) . Moreover, ezetimibe reduced the expressions of SREBP-1c and ChREBP, key transcriptional factors involved in the lipogenic gene expression, in response to insulin and glucose. Considering a potential role of SREBP-1c and ChREBP in the development of metabolic syndrome, our finding points to a novel therapeutic approach to metabolic syndrome by ezetimibe. Fig. 4 . Effect of NPC1L1 blockade on ROS production in the livers of ZOF rats. ZOF rats were treated for 4 wk with the Ve or Ez. A: mitochondria were isolated from the livers, and cholesterol was extracted and quantified (n ϭ 4 for each treatment). B: the amount of ROS in the livers was visualized by DHE staining (n ϭ 4 for each treatment). C: cytosol and mitochondria were isolated from the livers, and total glutathione was quantified (n ϭ 3 for each treatment). D: JNK and p38 phosphorylation were detected in whole liver extracts (n ϭ 4 for each treatment). E: total RNA was isolated from the livers, and then mRNA expression levels were determined using real-time PCR (n ϭ 4 for each treatment). *P Ͻ 0.05. NCF1 and -2, neutrophil cytosolic factor-1 and -2; COX2, cyclooxigenase-2; PERK, protein kinase-like endoplasmic reticulum kinase; XBP1s, spliced form of X-box-binding protein-1; ATF6, activating transcription factor 6; CHOP, C/EBP homologous protein.
Genetic ablation of NPC1L1 by shRNA also led to similar improvements in steatosis and insulin signaling. Taken together, these results strongly suggest a potential role for NPC1L1 and its blockade not only in hepatic steatosis but also in hepatic insulin resistance. Recently, the involvement of hepatic NPC1L1 in sterol transport was proposed (23, 33) , and the present findings suggest that the beneficial effects of ezetimibe are due primarily to its inhibition of NPC1L1 and subsequent cholesterol accumulation.
As reported previously (1, 4), human NPC1L1 is expressed predominantly in small intestine and liver, with detectable levels in lung, heart, brain, pancreas, and kidney. These observations and the expression of NPC1L1 in human hepatocytes ( Fig. 2A) reinforce our hypothesis to explore the physiological role of hepatic NPC1L1. Alhough its expression in adipocytes and skeletal muscles is relatively low (1), a role for NPC1L1 in these insulin target organs is yet to be examined.
FC accumulation in hepatocytes induces hepatic insulin resistance through several mechanisms. The importance of ROS in hepatic insulin signaling has been demonstrated repeatedly (18, 19, 21) . As expected, ezetimibe cancelled steatotic stimuli-mediated induction of oxidative stress. The potential contribution of ER stress to the development of insulin resistance has also been demonstrated. Recent reports have linked FC influx and ER stress in macrophages (19, 23) . In addition, enrichment of cholesterol in ER membranes causes its stress response, which leads to the induction of FoxO1, CHOP, and p38 (7, 29) . Therefore, inhibition of FC uptake by ezetimibe could ameliorate ER stress in the liver. As expected, blocking NPC1L1 by shRNA reduced ER stress in steatotic hepatocytes in vitro. In line with our observation, a recent study documented that the hepatic steatosis and lipid disorders copresent in obese insulin-resistant rodents are strongly related to the activation of hepatic ER stress through SREBP-1c and ChREBP (20) . Therefore, the reduction of ER stress by NPC1L1 blockade may improve hepatic steatosis and insulin resistance via inhibition of SREBP-1c and ChREBP.
Furthermore, ezetimibe reduced cholesterol contents in the mitochondrial compartment, one of the major organelles responsible for chronic metabolic disorders (17) . Taken together, NPC1L1 regulates intracellular ROS and ER stress by modulating intracellular cholesterol content, especially in mitochondria and ER (see Fig. 6 ). A: plasmid vector-mediated RNAi was performed using a control scramble (shCT) or NPC1L1 (shNPC1L1) in HuH7 cells. After 48 h, lysates were separated by SDS-PAGE and analyzed by Western blot analysis with the indicated antibodies (n ϭ 3 for each treatment). B-G: HuH7 cells were transfected with the control or NPC1L1 knockdown vector. After 36 h, the cells were depleted of cholesterol by incubation in 1% CDX for 60 min, after which FC (50 g/ml) was added to the medium without serum. B: after 24 h, cellular and mitochondrial T-Chol were extracted and quantified (n ϭ 3 for each treatment). C: after 60 min, TNF (25 ng/ml) was added to the medium. After 24 h, the cells were stimulated for 15 min with insulin (100 nM), and then p-Akt was detected in whole cell extracts (n ϭ 3 for each treatment). D: after 6 h, total RNA was isolated from the cells, and the mRNA expression levels were determined using real-time PCR (n ϭ 3 for each treatment). E: after 60 min, TNF (25 ng/ml) was added to the medium. After 24 h, the amount of ROS was visualized by DHE staining and quantified (n ϭ 3 for each treatment). F: total RNA was isolated from the cells, and the mRNA expression levels were determined using real-time PCR (n ϭ 3 for each treatment). G: after 24 h, the cells were stimulated for 15 min with or without TNF (25 ng/ml), and then JNK phosphorylation was detected in whole cell extracts (n ϭ 3 for each treatment). H: after 6 h, whole cell extracts were collected and p38 phosphorylation was detected (n ϭ 3 for each treatment). *P Ͻ 0.05; **P Ͻ 0.01.
In conclusion, our findings indicated that hepatic NPC1L1 contributes to hepatic insulin resistance through FC accumulation and subsequent ROS generation and ER stress. Thus the inhibition of NPC1L1-dependent cholesterol uptake may be a suitable therapeutic target for treatment of not only dyslipidemia but also broader aspects of metabolic diseases, such as type 2 diabetes. Fig. 6 . Proposed mechanisms by which NPC1L1 blockade improves hepatic insulin resistance. NPC1L1-dependent cholesterol uptake in the liver induces cholesterol accumulation and reduces glutathione level in the mitochondria. It also increases endoplasmic reticulum (ER) stress manifested by upregulation of FoxO1 and p38 activation. These signals enhance cellular ROS and influence insulin signaling via downregulation of Akt activation. Ez or shNPC1L1 inhibits the internalization of hepatic NPC1L1, leading to a decreased uptake of cholesterol. Thus it decreased ROS and increased insulin sensitivity and improved insulin resistance. Mito, mitochondrion; mGSH, mitochondrial glutathione.
